OncoSec Medical Inc (ONCSQ)

[hschlauch]

This is a great read - nothing beats understanding fundamental cellular biology.

If anyone knows anything about checkpoint inhibitors it is this guy, James Allison.

https://www.sciencedaily.com/releases/2017/08/170810124952.htm


Checkpoint inhibitors fire up different types of T cells to attack tumors

These cells are boosted by anti-PD-1, but they keep their exhausted phenotype, which suggests they'll shut down when the PD-1 antibody is withdrawn," Allison said. This supports the need to give the drug for long periods, and current anti-PD-1 regimens provide a year or two of treatment

.

How can you achieve sustained release of PD1 antibodies without so many repeat administrations? Through intramuscular electroporation of encoded genes - allow the body to manufacture its own antibodies.

CTLA-4 blockade is thought to act at the initiation of immune response, while PD1 is used by tumors to shut down an immune response that is under way by using PD-L1 to turn T cells off.

And who has published patent applications on intratumoral delivery of encoded CTLA-4 on plasmids also containing costimulatory molecules and cytokines? Yes, Oncosec.